Notching up a new therapeutic strategy for non-small cell lung carcinoma (NSCLC)

Oncotarget. 2012 Sep;3(9):917-8. doi: 10.18632/oncotarget.671.

Abstract

Our results open a new therapeutic opportunity to treat NSCLC using GSIs. Interestingly, GSIs have been used in long-term treatments in Alzheimer´s patients without major side effects (although without improving the course of the disease). The accumulated knowledge on the pharmacology of GSIs should pave the way to test these compounds in NSCLC patients.

Publication types

  • Editorial

MeSH terms

  • Amyloid Precursor Protein Secretases / antagonists & inhibitors*
  • Amyloid Precursor Protein Secretases / metabolism
  • Animals
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / metabolism
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Disease Models, Animal
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / pathology
  • Mice
  • Protease Inhibitors / pharmacology*
  • Receptors, Notch / metabolism*
  • Signal Transduction

Substances

  • Protease Inhibitors
  • Receptors, Notch
  • Amyloid Precursor Protein Secretases